文献速递腹部介入CT

基于CT的影像组学列线图预测肝细胞癌合并门静脉癌栓患者经药物洗脱微球经动脉化疗栓塞治疗后的生存

CT-based radiomics nomogram for prediction of survival after transarterial chemoembolization with drug-eluting beads in patients with hepatocellular carcinoma and portal vein tumor thrombus.
PubMed 文献 · Eur Radiol · 2023-07-12

联合模型在训练队列和验证队列的C-index分别为0.814和0.792,对12个月总生存的预测表现令人满意。

要点

  • 门静脉癌栓类型和肿瘤数目是总生存的显著临床预测因素。
  • 基于3个影像组学特征和2个临床指标的CT列线图可用于预测12个月总生存。
  • 联合模型C-index训练队列0.814、验证队列0.792,优于单纯影像组学模型。

核心结论

  • 门静脉癌栓类型和肿瘤数目影响接受药物洗脱微球经动脉化疗栓塞治疗的肝细胞癌合并门静脉癌栓患者的总生存,联合临床-影像组学模型表现令人满意。

研究设计与样本

  • 回顾性研究,从两家机构纳入训练队列69例和验证队列31例,中位随访15个月,从每幅基线CT图像提取396个影像组学特征,采用变量重要性和最小深度筛选特征构建随机生存森林模型。

关键影像表现/征象

  • 采用动脉期图像提取影像组学特征。
  • 共筛选出3个影像组学特征用于模型构建。
  • 门静脉癌栓类型和肿瘤数目被证实为总生存的显著临床指标。

诊断标准与关键数值

  • 影像组学模型C-index在训练队列为0.759、验证队列为0.730。
  • 联合模型C-index在训练队列为0.814、验证队列为0.792。
  • 联合模型对比影像组学模型预测12个月总生存的IDI在两个队列中均有显著性。

临床应用与阅片要点

  • 作者推荐使用由3个影像组学特征和2个临床指标组成的CT影像组学列线图预测初次接受药物洗脱微球经动脉化疗栓塞治疗的肝细胞癌合并门静脉癌栓患者的12个月总生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To develop and validate a CT-based radiomics model for the prediction of the overall survival (OS) of patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT) treated with drug-eluting beads transarterial chemoembolization (DEB-TACE).

METHODS: Patients were retrospectively enrolled from two institutions for the constitution of training (n = 69) and validation (n = 31) cohorts with a median follow-up of 15 months. A total of 396 radiomics features were extracted from each baseline CT image. Features selected by variable importance and minimal depth were used for random survival forest model construction. The performance of the model was assessed using the concordance index (C-index), calibration curves, integrated discrimination index (IDI), net reclassification index (NRI), and decision curve analysis.

RESULTS: Type of PVTT and tumor number were proved to be significant clinical indicators for OS. Arterial phase images were used to extract radiomics features. Three radiomics features were selected for model construction. The C-index for the radiomics model was 0.759 in the training cohort and 0.730 in the validation cohort. To improve the predictive performance, clinical indicators were integrated into the radiomics model to form a combined model with a C-index of 0.814 in the training cohort and 0.792 in the validation cohort. The IDI was significant in both cohorts for the combined model versus the radiomics model in predicting 12-month OS.

CONCLUSIONS: Type of PVTT and tumor number affected the OS of HCC patients with PVTT treated with DEB-TACE. Moreover, the combined clinical-radiomics model had a satisfactory performance.

CLINICAL RELEVANCE STATEMENT: A CT-based radiomics nomogram, which consisted of 3 radiomics features and 2 clinical indicators, was recommended to predict 12-month overall survival of patients with hepatocellular carcinoma and portal vein tumor thrombus initially treated with drug-eluting beads transarterial chemoembolization.

KEY POINTS: • Type of portal vein tumor thrombus and tumor number were significant predictors of the OS. • Integrated discrimination index and net reclassification index provided a quantitative evaluation of the incremental impact added by new indicators for the radiomics model. • A nomogram based on a radiomics signature and clinical indicators showed satisfactory performance in predicting OS after DEB-TACE.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Cheng S, Hu G, Jin Z, et al. CT-based radiomics nomogram for prediction of survival after transarterial chemoembolization with drug-eluting beads in patients with hepatocellular carcinoma and portal vein tumor thrombus. Eur Radiol. 2023. PMID: 37436507. doi:10.1007/s00330-023-09830-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。